Harvard Bioscience (NASDAQ:HBIO) Stock Price Passes Below Two Hundred Day Moving Average – What’s Next?

Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.58 and traded as low as $1.93. Harvard Bioscience shares last traded at $1.98, with a volume of 83,714 shares changing hands.

Harvard Bioscience Stock Performance

The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06. The stock has a market capitalization of $84.19 million, a P/E ratio of -5.85 and a beta of 1.27. The business has a 50-day moving average price of $2.15 and a 200 day moving average price of $2.56.

Institutional Investors Weigh In On Harvard Bioscience

Hedge funds have recently added to or reduced their stakes in the stock. State Street Corp raised its position in shares of Harvard Bioscience by 1.1% in the 3rd quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock worth $1,930,000 after purchasing an additional 7,763 shares during the last quarter. Rhumbline Advisers increased its stake in Harvard Bioscience by 24.9% during the 2nd quarter. Rhumbline Advisers now owns 47,753 shares of the medical instruments supplier’s stock valued at $136,000 after purchasing an additional 9,512 shares in the last quarter. Royce & Associates LP raised its holdings in Harvard Bioscience by 0.7% in the third quarter. Royce & Associates LP now owns 1,451,450 shares of the medical instruments supplier’s stock worth $3,904,000 after buying an additional 10,000 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Harvard Bioscience in the third quarter worth approximately $30,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Harvard Bioscience by 63.0% during the third quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock valued at $79,000 after buying an additional 11,397 shares during the last quarter. 80.87% of the stock is owned by institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.